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Rejection was more common for manufacturer’s comments on outcomes (6/8; 75%) 
and comparators (8/13; 61.5%). Rate of final recommendation by NICE was higher 
for those MS where all (29/40; 74%) or certain changes (14/20; 74%) requested by 
the manufacturer were implemented in the final scope than for those where NICE 
rejected all manufacturer requests (7/11; 64%), and similar to overall recommenda-
tion rate (66/91; 73%). ConClusions: These data highlight that the initial scope 
frequently does not meet manufacturer’s expectations. However, manufacturer’s 
suggestions are often incorporated in the final scope. NICE not implementing manu-
facturer’s suggestions to the final scope does not decrease the likelihood of being 
granted funding.
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objeCtives: Biosimilars and biobetters are subsequent versions of licensed innova-
tor biotherapeutics. Whereas biosimilars are comparable to the originator product 
in terms of quality, safety and efficacy, biobetters incorporate intentional modifi-
cations to the originator molecular profile with the aim of producing a superior 
product. This distinction between biosimilars and biobetters has important impli-
cations from a regulatory perspective, with biosimilars following class-specific 
guidance whereas biobetters are considered innovator drugs. This study sought 
to examine and compare the regulatory and reimbursement approaches to the 
appraisal of biobetters and biosimilars. Methods: Biobetters and biosimilars of 
the same product class were identified, and qualitative analyses of the recommen-
dations by indication, evidence considered, and key decision drivers were under-
taken using available regulatory and HTA reimbursement decision documentation 
from six European countries. Results: Findings for filgrastim are presented as 
an example; 7 biosimilars, and the pegylated filgrastims (pegfilgrastim and lipegfil-
grastim) considered biobetters, were identified. Biosimilar filgrastims were granted 
European marketing authorisation based on demonstration of clinical comparabil-
ity to the originator filgrastim in one indication and extrapolation of the results 
to all 5 approved indications. Pegfilgrastim demonstrated clinical non-inferiority 
to filgrastim in one indication and was approved solely for this indication; the 
subsequently developed lipegfilgrastim was approved for the same indication but 
used pegfilgrastim as the comparator. Similar to biosimilar filgrastims, economic 
evidence in the form of cost-minimisation analyses was considered in HTA recom-
mendations of both pegylated filgrastims. This differs from the approach for certain 
other biobetters that have demonstrated clinical superiority and cost-effectiveness 
versus their originator. ConClusions: Biosimilars and biobetters are subject to 
distinct regulatory processes and the decision driving factors for reimbursement 
also differ among currently licensed biobetters. With the development of these 
products gaining momentum, it will be interesting to observe how the appraisal 
processes evolve to address the scope and variety of emerging biobetters.
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objeCtives: In Germany, with the introduction of the Pharmaceutical Market 
Restructuring Act (AMNOG) in January 1st2011, pricing and reimbursement deci-
sions for new drugs have been driven by the early benefit assessment (EBA). G-BA 
can decide to set or not a time limitation to the decision. The objectives of this 
study were, first, to review the number of time-limited decisions over time and 
second, to identify drivers of these decisions. Methods: G-BA’s decisions, from the 
introduction of AMNOG Law to June 1st2014, were reviewed. Exempted and/or 
cancelled procedures were excluded. Results: As of June 1st 2014, 76 EBAs were 
concluded and time limits, from 1 to 5 years, were imposed on 28% (21/76) of these 
decisions. Short-term restrictions (≤ 2 years) accounted for 52% (11/21) of the time-
limited decisions and long-term (> 2 years) for 48% (10/21). Time-limited decisions 
concerned largely oncology drugs (62%; 13/21), followed by endocrine/metabolic 
drugs (19%; 4/21) and neurology drugs (10%; 2/21). The number of time limited deci-
sions increased over the studied period, from none (0/2) of the decisions in 2011 to 
16% (3/19) in H1 2012, 38% (3/8) in H2 2012, 20% (3/15) in H1 2013, 35% (7/20) in H2 
2013 and reaching 42% (5/12) from January 1st to June 1st 2014 decisions. Time-limited 
decisions were triggered by one or several factors, with safety concerns being the 
major driver (38%; 8/21). Other drivers were uncertainties of outcomes (33%; 7/21), 
ongoing studies (33%; 7/21), lack of data (24% (5/21), European Medicine Agency’s 
(EMA) conditional approval (19%; 4/21), design uncertainty (10%; 2/21), inappropriate 
comparator (10%; 2/21), quality of life concerns (10%; 2/21), and EMA requirements 
for post-authorisation studies or risk management plan (10%; 2/21). ConClusions: 
An increasing trend for time-limited decisions was observed. Time restricted deci-
sions have become a major uncertainty management tool in Germany.
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objeCtives: Ultra-orphan diseases are extremely rare conditions many of which 
are severe, chronic, and progressive with high mortality rates. There is a growing 
number of therapies for ultra-rare diseases currently on the market. Reimbursement 
decisions for these therapies have been characterized by reduced evidence require-
ments with unmet need weighing heavily into health technology assessment (HTA) 
and reimbursement decision-making; as well as a generally wide pricing latitude. 
To gain insight into evolving market access requirements, we conducted a review 
of pan-European ultra-orphan therapy HTA requirements and reimbursement deci-
sions. Methods: Applying the National Institute for Health and Care Excellence 
(NICE) definition for ultra-orphan diseases (prevalence of ≤ 1/50,000), full European 
HTA reports on ultra-orphan therapies published through May 2014 were identified 
and reviewed to compare evidence requirements and reimbursement decisions 
across countries for health economic, clinical, and value based criteria. Results: 
Over sixty published ultra-orphan HTAs were identified across nine markets. A 
small portion of these submissions were rejected for reimbursement largely due 
to lack of evidence on clinical benefit. For therapies recommended with access 
restrictions, payers often requested additional follow-on studies or ongoing moni-
toring of patients by manufacturers. With respect to economic evidence evaluation, 
reimbursement decisions predominately hinged on therapy cost per patient per 
year, rather than cost-effectiveness. More recent assessments also evaluated qual-
ity of life evidence and input from patient groups. ConClusions: As health care 
budgets become more strained, ultra-orphan therapies priced at a premium have 
come under increased scrutiny from HTA agencies and payers to demonstrate value 
for money. In order to achieve optimal market access, manufacturers must consider 
continually evolving stakeholder evidence requirements and develop clinical and 
health economic value plans that demonstrate how their ultra-orphan therapies 
provide health gain instead of disease stabilization.
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objeCtives: Ultra-orphan diseases affect a very small patient population, defined 
by the National Institute for Health and Care Excellence (NICE) as those diseases 
with a prevalence of ≤ 1: 50,000. Medicines for these indications are difficult to 
develop in part due to challenges associated with recruiting for clinical trials 
from a small patient population. Within this context, global payer bodies have 
assessed these therapies with modified evidence requirements and opportunity 
for very high prices. We performed a health technology assessment (HTA) review 
of two ultra-orphan products – eculizumab/Soliris and iduronate-2-sulfatase (IDS)/
Elaprase – to gain insight into the evolving HTA evidence requirements for ultra-
orphan medicines and comparatively evaluate key decision drivers across geogra-
phies. Methods: We scanned global HTAs published before end of May 2014 to 
identify the two most widely assessed ultra-orphan therapies that have variable 
reimbursement decision outcomes (eculizumab/Soliris and IDS/Elaprase). To evalu-
ate pivotal decision drivers, we analyzed HTAs across several criteria, including 
clinical efficacy, unmet need, strength of evidence, cost-effectiveness and burden 
of illness. Results: We identified HTAs in seven countries. For both products, 
reimbursement decisions varied across agencies. Key decision drivers included 
cost-effectiveness, clinical efficacy, risk-sharing schemes, and lowered evidence 
requirements/ special criteria for ultra-orphan medicines. Assessments rejecting 
Soliris and Elaprase (e.g., Australia, Canada, UK) did so based on cost-effectiveness 
and lack of long-term survival data. Notably, the NICE Highly Specialized Technology 
Committee requested unprecedented justification of Soliris pricing. Some agencies 
(e.g, Scottish Medicines Consortium [SMC]) preemptively rejected the products due 
to manufacturer non-submission of required data. In Australia, Soliris gained recom-
mendation alongside a risk-sharing scheme while Elaprase gained recommendation 
under Life Saving Drugs Program criteria. ConClusions: Eculizumab and IDS are 
among a select list of therapies commanding very high prices globally. This study 
demonstrates variability in decision criteria and approaches across HTA agencies 
for such high-priced ultra-orphan products.
PHP163
EvidEncE-bAsEd mARkEt AccEss vAluE REsouRcE: nAvigAting tHE 
HuRdlEs foR A biologic obtAining A licEnsE in A sEcond indicAtion in 
kEy EuRoPEAn countRiEs
Hogue S.1, Bjoerk B.2, Walker A.3, Balp M.M.2, Fernandez M.4, Quijano M.2, Ling C.S.5, Heyes A.E.5
1RTI-Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, 
Switzerland, 3University of Glasgow, Glasgow, UK, 4RTI Health Solutions, RTP, NC, USA, 5RTI 
Health Solutions, Manchester, UK
objeCtives: Market access for an innovative technology, such as a biologic 
obtaining a license in a second indication, can be complex and time consuming. 
Reimbursement is critical to rapid adoption of and optimal patient access to a new 
technology. This study aimed to determine the best approach for communicating 
value and providing field-based staff with value resources to facilitate dialogue 
with stakeholders in various scenarios. Methods: We conducted desktop research 
of published literature, health technology assessment reports, clinical trials data, 
and third-party websites to identify the critical path and data most valuable to 
reimbursement decision making in order to prepare a communication resource. 
We conducted a country-affiliate workshop and qualitative one-on-one interviews 
with payer decision makers in several key markets to understand funding flow and 
the most appropriate means of communicating value to external decision mak-
ers. Results: The process and restrictions for biologics may be stricter than for 
other medications because of perceived high cost. There are multiple appropriate 
access pathways for various settings of care, all with varying requirements and 
value drivers. It is critical to understand the needs of external decision makers 
and provide field-based staff with a consistent yet customizable means of com-
municating the value of new technologies. All evidence and insights were synthe-
sized into an evidence-based market access value resource for key stakeholder 
